Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Inotuzumab Ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The Phase 1B of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory CD22+ BCP-ALL pediatric patients were enrolled....

Descripción completa

Detalles Bibliográficos

Autores principales:	Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, Yilin Jiang, Vincent H. J. van der Velden, H. Berna Beverloo, Barbara Sleight, Franco Locatelli, Benoit Brethon, Claudia Rossig, Gernot Engstler, Anna Nilsson, Benedicte Bruno, Arnaud Petit, Bella Bielorai, Carmelo Rizzari, Fanny Rialland, Alba Rubio-San-Simón, Francisco J. Bautista Sirvent, Cristina Diaz-de-Heredia, Susana Rives, Christian M. Zwaan
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Ferrata Storti Foundation 2024-01-01
Colección:	Haematologica
Acceso en línea:	https://haematologica.org/article/view/11398
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!